EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticu s

Aurélie Hanin iD, Clémence Marois iD, Martin Guillemaud iD, Mario Chavez iD, Léa Cosme iD, Zineb Hayatou iD, Aurore Besnard, Gwen Goudard, Véronique Masson, Louis Cousyn iD, Margaux Cheval iD, Jérôme A Denis iD und 23 weitere

Epilepsia · 2026-05 · 67 (5) · 2326-2346

DOI: 10.1002/epi.70146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 16.02.2026. Verfasst von Aurélie Hanin und 34 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Institut National de de la Santé et de Recherche Médicale (INSERM), Centre Nation…. Hauptthemen laut MEDLINE: Status Epilepticus, Drug Resistant Epilepsy, Cytokines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daniel Raymond Wong Neurology fund at Yale, FFRE-Paratonnerre, CURE Epilepsy's 2023 Rare Epilepsy Partnership Award, in partnership with the NORSE Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase.

Methods

We enrolled 93 cNORSE patients from the Pitié‐Salpêtrière Hospital and the Yale NORSE/FIRES biorepository (2013–2025). Serum and cerebrospinal fluid (CSF) samples were collected during status epilepticus (SE), with outcomes assessed 6–12 months after resolution. To investigate post‐cNORSE epilepsy, we compared 39 post‐cNORSE patients (25 with paired acute samples) to 40 patients with temporal lobe epilepsy due to hippocampal sclerosis (TLE‐HS) and 20 with chronic immune‐mediated encephalitis.

Results

During cNORSE, elevated innate cytokines (serum CXCL8, CCL2; CSF IL‐6, CXCL8, CCL2, MIP‐1α, G‐CSF) and brain injury biomarkers (serum and CSF neurofilament light chain [NfL], CSF neuron‐specific enolase) correlated with worse functional outcomes. Multivariate models demonstrated that adding serum NfL to cytokines improved poor outcome prediction (area under the curve = .75). In contrast, no acute biomarker predicted post‐cNORSE epilepsy, which was instead associated with prolonged SE, magnetic resonance imaging abnormalities, and the need for more intensive treatment. In paired analyses, most serum cytokines normalized during the chronic phase, particularly IL‐6, IL‐10, and IL‐1β, although new adaptive immune disturbances (IL‐17A, IL‐12p70, TNFα) appeared in 20% of patients. No chronic elevations of innate cytokines were observed in post‐cNORSE patients. Conversely, elevated age‐adjusted NfL levels were more frequent in post‐cNORSE epilepsy (64%) than encephalitis (45%) and TLE‐HS (20%), ( p < .001), with elevated NfL levels correlating with poor functional outcomes ( p = .019). Significance Innate immune activation is a hallmark of acute cNORSE but largely resolves in the chronic phase, arguing against persistent innate inflammation as the driver of post‐cNORSE epilepsy. In contrast, persistently elevated NfL levels suggest ongoing axonal injury, potentially contributing to poor outcomes. Integrating inflammatory and neuroaxonal injury biomarkers may improve risk stratification and guide long‐term management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Status EpilepticusDrug Resistant EpilepsyCytokinesHumansMaleFemaleAdultBiomarkersHippocampal SclerosisMiddle AgedNeurofilament ProteinsYoung AdultEncephalitis

Stichwörter der Autor:innen

NORSE epilepsyNORSE outcome postbrain injury biomarkerscytokinesnew‐onset refractory status epilepticus

Substanzen

BiomarkersCytokinesNeurofilament Proteinsneurofilament protein L

Autor:innen und Institutionen

  • Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Institut National de de la Santé et de Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Institut National de la Recher…
  • Department of Metabolic Biochemistry, DMU BioGeMH, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, Pitié-Salpêtrière-Charles Foix University Hospital, Paris, France.
  • Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Neuro-Intensive Care Unit, Paris, France.
  • Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital de la Pitié-Salpêtrière, Sorbonne Université, Epilepsy Unit and Department of Clinical Neurophysiology, European Reference Network EpiCARE, Paris, France.
  • Sorbonne Université, Institut National de de la Santé et de Recherche Médicale (INSERM) UMR_S 938, Centre de Recherche Saint-Antoine, Paris, France.
  • Assistance Publique Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Cellular and Molecular Oncobiology, Paris, France.

ORCID-Profile: Aurélie Hanin, Clémence Marois, Martin Guillemaud, Mario Chavez, Léa Cosme, Zineb Hayatou, Louis Cousyn, Margaux Cheval, Jérôme A Denis, Foudil Lamari, Francesca Bisulli, Krista Eschbach, Raquel Farias-Moeller, Nicolas Gaspard, Elizabeth E Gerard, Giada Giovannini, Teneille Gofton, Margaret T Gopaul, Marissa Kellogg, Stefano Meletti, Lorenzo Muccioli, Elena Pasini, Olga Taraschenko, Nathan Torcida, Mark S Wainwright, Ji Yeoun Yoo, Nora Wong, Dominique Bonnefont-Rousselot, Sophie Demeret, Lawrence J Hirsch, Vincent Navarro

Förderung

  • Daniel Raymond Wong Neurology fund at Yale
  • FFRE-Paratonnerre
  • CURE Epilepsy's 2023 Rare Epilepsy Partnership Award, in partnership with the NORSE Institute
  • NORSE/FIRES Research Fund at Yale

Zitieren

APA

Hanin, A., Marois, C., Guillemaud, M., Chavez, M., Cosme, L., Hayatou, Z., Besnard, A., Goudard, G., Masson, V., Cousyn, L., Cheval, M., Denis, J. A., Alkouri, R., Lamari, F., Bisulli, F., Eschbach, K., Farias-Moeller, R., Gaspard, N., Gerard, E. E., …, & Navarro, V. (2026). Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticu s. Epilepsia, 67(5), 2326-2346. https://doi.org/10.1002/epi.70146

Vancouver

Hanin A, Marois C, Guillemaud M, Chavez M, Cosme L, Hayatou Z, et al. Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticu s. Epilepsia. 2026;67(5):2326-2346. doi:10.1002/epi.70146

BibTeX
@article{Hanin2026,
  author = {Hanin, Aurélie and Marois, Clémence and Guillemaud, Martin and Chavez, Mario and Cosme, Léa and Hayatou, Zineb and Besnard, Aurore and Goudard, Gwen and Masson, Véronique and Cousyn, Louis and Cheval, Margaux and Denis, Jérôme A and Alkouri, Rana and Lamari, Foudil and Bisulli, Francesca and Eschbach, Krista and Farias-Moeller, Raquel and Gaspard, Nicolas and Gerard, Elizabeth E and Giovannini, Giada and Gofton, Teneille and Gopaul, Margaret T and Kellogg, Marissa and Meletti, Stefano and Muccioli, Lorenzo and Pasini, Elena and Taraschenko, Olga and Torcida, Nathan and Wainwright, Mark S and Yoo, Ji Yeoun and Wong, Nora and Bonnefont-Rousselot, Dominique and Demeret, Sophie and Hirsch, Lawrence J and Navarro, Vincent},
  title = {Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticu s},
  journal = {Epilepsia},
  year = {2026},
  volume = {67},
  number = {5},
  pages = {2326--2346},
  doi = {10.1002/epi.70146}
}
Kostenlos starten →